rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

GT Biopharma, Inc.

GTBP · Nasdaq

Health CareBiotechnologyNot moving yet

GTBP stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 18.7% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
55 (+19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders55+19 on the quarter
New · exited22 · 4
Reported value$967K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026376,399$184K-75,476−16.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026266,788$131K-27,671−9.4%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026225,938$111K00.0%
Everhart Financial Group, Inc.new · filed 9 Jul 2026100,000$49K+100,000
Arax Advisory Partnersunchanged · filed 10 Aug 202693,627$46K00.0%
Opal Wealth Advisors, LLCnew · filed 20 Jul 202681,811$40K+81,811
NORTHERN TRUST CORPnew · filed 13 Aug 202675,461$37K+75,461
49 WEALTH MANAGEMENT, LLCnew · filed 10 Aug 202664,000$31K+64,000
ALONGSIDE, LLCnew · filed 14 Aug 202664,000$31K+64,000
Cetera Investment Advisersnew · filed 12 Aug 202655,936$27K+55,936
31 Dec 2023 – 30 Jun 2026
42953Dec 23Sep 24Mar 25Dec 25Jun 26

Everyone who traded it

Alan Louis Urban Company insiderChief Financial Officer · last 4 Sep 20250 · 0
Charles J. Casamento Company insiderDirector · last 4 Sep 20250 · 0
David C. Mun-Gavin Company insiderDirector · last 4 Sep 20250 · 0
Hilary Kramer Company insiderDirector · last 4 Sep 20250 · 0
Michael Martin Breen Company insiderCEO and Director · last 4 Sep 20251 · 0
Manu Ohri Company insiderCFO & Secretary · last 11 Aug 20231 · 0
Bruce Wendel Company insiderDirector · last 27 Jan 20232 · 0
Rajesh C. Md Shrotriya Company insiderDirector · last 27 Jan 20230 · 0
Gregory Berk Company insiderPres. of R&D, CMO · last 15 Jul 20220 · 0
Gavin Choy Company insiderActing Chief Financial Officer · last 31 Dec 20210 · 0
Steven W. Weldon Company insiderOther · last 22 Dec 20200 · 9
Tony Cataldo Company insiderCEO · last 2 Jun 20200 · 2

Same industry

MRNA ModernaLeading+167%
IOVA Iovance BiotherapeuticsLeading+141%
ABCL AbCellera BiologicsLeading+57%
ENTX Entera BioLeading+52%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+47%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Cash conversionFY 2025 · to 30 Sep 2025-107%
Share count trendFY 2025 · to 23 Feb 202623.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$6.8M

Analyst forecasts

No analyst forecasts yet.